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Introduction {#sec1}
============

Glycolysis constitutes an essential metabolism among various organisms, serving not only as an energy source but also for the synthesis of macromolecules ([@bib46]). The regulation of glycolysis depends on several factors including growth conditions, differentiation status, and environmental stress. In mammalian cells, metabolic adaptation in glycolysis is mediated partly by the activation of specific signaling modules, followed by the transcriptional upregulation of glycolytic enzymes ([@bib6]). In addition to transcriptional factors, several other molecules including signals from nutritional stress, oncogenic stimuli, and posttranscriptional regulators are also deeply involved in glycolytic regulation ([@bib29]).

Fine-tuning of glycolysis is required to maintain physiological homeostasis in normal cells and tissues, and dysregulated glycolysis is closely related to pathological features. Impaired glycolysis *in vivo* is associated with dysfunction in various tissues and degenerative disorders ([@bib14]; [@bib42]). Conversely, the pathological enhancement of glycolysis is also observed in several diseased states, such as inflammation ([@bib5]), ischemia, and the cancerous Warburg effect in association with increase of activity and protein levels for multiple glycolytic enzymes ([@bib50]). Although normal cells may adapt to hypoxic conditions by enhancing anaerobic glycolysis and limiting energy demands, cancer cells *in vivo* continue to grow even in hypoxia, which requires excess glycolysis as a maladaptive metabolism in the core of solid tumors. However, the Warburg effect cannot be explained simply as a consequence of cellular adaptation to hypoxia, as cancer cells maintain enhanced glycolysis even in standard tissue culture conditions (20% oxygen) or in circulating blood ([@bib24]). Therefore, a rising question is how the Warburg effect is linked to the other cancerous properties besides adaptation to hypoxia.

Phosphoglycerate mutase (PGAM) is a glycolytic enzyme that converts 3-phosphoglycerate into 2-phosphoglycerate as an isomerase ([@bib36]). PGAM consists of two isoforms, PGAM1 and PGAM2, termed also as brain- and muscle-forms, respectively, both of which display a significant similarity in their sequences (79% identity) and enzymatic activities ([@bib22]; [@bib28]; [@bib54]). Recent reports suggest that PGAM represents a key factor connecting glycolysis to physiological homeostasis. PGAM supports anti-oxidative defense not only by the reduction of mitochondrial reactive oxygen species ([@bib22], [@bib23]) but also via activation of the pentose phosphate pathway ([@bib16]). Moreover, the p53/Mdm2 axis promotes proteolysis of PGAM during senescence-inducing stress ([@bib28]), which is consistent with reports that p53 inactivation enhances glycolysis in cancer ([@bib2]). In addition to the ubiquitination, PGAM activity is post transcriptionally modulated by the phosphorylation or acetylation ([@bib49]; [@bib52]). Several studies also implicate the involvement of PGAM in human disease. Although PGAM protein and activity are upregulated in many cancerous tissues ([@bib11]), patients with PGAM deficiencies are also reported ([@bib31]). However, the precise regulatory role of PGAM in glycolysis remains unclear.

Here, we report a previously unappreciated role for PGAM in cancerous glycolytic regulation. We observed that PGAM significantly affected the global profiles of glycolysis in cancerous cells. PGAM cooperated with Chk1, previously known as a checkpoint kinase for p53, to boost glycolysis under oncogenic conditions, but not in standard cells. The significance of the PGAM-Chk1 interaction in cancerous glycolysis was validated by several lines of evidence with genetic or chemical ablation of PGAM-Chk1 binding, especially under oncogenic Ras expressing conditions. Thus, PGAM and Chk1 cooperated to regulate cancerous glycolysis.

Results {#sec2}
=======

PGAM Overexpression *In Vivo* Promotes Chemically Induced Tumorigenesis with Global Increase in Glycolytic mRNAs {#sec2.1}
----------------------------------------------------------------------------------------------------------------

We previously reported that heart-specific *Pgam2*-transgenic (Tg) mice displayed almost normal glycolytic features in the heart ([@bib33]). However, the impact of global PGAM overexpression *in vivo* remains unclear. As it has been demonstrated that the overexpression of either PGAM isoform confers similar physiological impact ([@bib22]; [@bib28]; [@bib54]), we utilized *Pgam2*-Tg mice, which exhibited a significant increase of PGAM protein in the whole body by the *CAG*-promoter driven *Pgam2-FLAG* transgene ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib28]). Global overexpression of PGAM *in vivo* did not affect the profiles for glycolytic mRNAs among the various tissues (skin, liver, kidney, muscle, WAT, lung, or heart) under physiological conditions or in MEFs under standard culture conditions ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Although both isoforms of PGAM were expressed in skin of wild-type mice ([@bib28]), however, we noticed that skin in *Pgam2*-Tg mice was more vulnerable to inflammation caused by a proinflammatory agent, 12-O-tetradecanoylphorbol-13-acetate (TPA) ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). These findings prompted further investigation into the possibility that PGAM overexpression *in vivo* may affect glycolysis under TPA stress. For this purpose, we applied a protocol of chemically induced carcinogenesis utilizing 7,12-dimethylbenz\[a\]anthracene (DMBA) initiation followed by TPA promotion in mice skin from control and *Pgam2-*Tg mice ([Figure S2](#mmc1){ref-type="supplementary-material"}C). We observed that the total number of tumors in *Pgam2*-Tg mice was slightly increased ([Figure S2](#mmc1){ref-type="supplementary-material"}D), whereas the tumor sizes were strikingly larger than those of control mice throughout the protocol. At the early stage of the experimental process (8--12 weeks) small tumors in *Pgam2*-Tg mice were already observed ([Figure 1](#fig1){ref-type="fig"}A, top panel). Subsequently (12--24 weeks), some tumors in the *Pgam2*-Tg mice grew to over 6 mm in their diameters, which was not observed in control mice ([Figure 1](#fig1){ref-type="fig"}A, middle and bottom panels). Notably, some of the largest tumors in the *Pgam2*-Tg mice were accompanied by moderate-to-severe ulceration as shown in [Figure 1](#fig1){ref-type="fig"}B. At the end of the protocol (24 weeks), pathologic analysis was performed for all tumors in mice. Histologically, tumors in both groups showed acanthosis and hyperkeratosis. All tumors in the control mice were pathologically benign (squamous cell papillomas), whereas 3 of 25 tumors that developed in *Pgam2*-Tg mice showed marked dyskeratosis, numerous mitoses, and severe disturbances of stratification, which are characteristic of squamous cell carcinoma (SCC) ([Figures 1](#fig1){ref-type="fig"}C and 1D).Figure 1PGAM Overexpression *In Vivo* Promotes Chemically Induced Tumorigenesis with Significant Increment in Glycolytic mRNAsChemical-induced skin tumorigenesis was performed. Control (*n* = 7) and *Pgam2-Tg* mice (*n* = 7) were first treated with DMBA followed by TPA treatment twice a week.(A) Comparison of tumor numbers between control (wild-type) and *Pgam2-Tg* mice. Tumors were classified into three subgroups according to their diameters (top panel for tumor size \<3 mm; middle panel, 3--6 mm; and bottom panel, \>6 mm). The average number of tumors per mouse was compared at the indicated time points.(B) Representative tumors in control or *Pgam2-Tg* mice at 24 weeks are indicated.(C and D) Histopathological analysis of skin tumors. (C) Skin papillomas in control (left panel) and SCC in *Pgam2-Tg* (right panel) with hematoxylin and eosin staining. Scale bar indicates 200 μm. (D) Summary of pathologic diagnoses of skin tumors in control and *Pgam2-Tg* mice.(E) Comparison of mRNA levels for glycolytic enzymes between control and *Pgam2-Tg* mice. The results in non-tumor forming skin, skin papillomas, and skin SCCs are shown. Data for the indicated genes are shown as relative values against the counterparts in non-tumor-forming skin from control mice. Abbreviations for glycolytic enzymes were shown in [Figure S1](#mmc1){ref-type="supplementary-material"}. ∗p \< 0.05 and ∗∗p \< 0.005, Dunnett\'s multiple comparison test. Data represent the mean ± SEM.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Notably, we identified clear differences in the mRNA profiles of glycolytic enzymes in the skins of this setting. The levels of glycolytic mRNAs were markedly increased both in papillomas and in skins without tumors from *Pgam2*-Tg mice compared with those in control mice ([Figure 1](#fig1){ref-type="fig"}E). In addition, the expression of these mRNAs was further enhanced in malignant tumors from *Pgam2-Tg* skin than in benign papillomas of the same genetic background ([Figure 1](#fig1){ref-type="fig"}E). Thus, the overexpression of PGAM promotes the expression of glycolytic mRNAs *in vivo* in chemically induced tumorigenesis.

Abrogation of PGAM Decreases Glycolytic mRNAs in Cancer Cells but Not in Standard Cells *In Vitro* {#sec2.2}
--------------------------------------------------------------------------------------------------

We next examined the impact of PGAM inactivation on glycolytic profiles *in vitro*. First, *PGAM1* siRNA was transfected into cancer cell types in which *PGAM1* is dominantly expressed: non-small cell lung carcinoma (H1299) and squamous cell carcinoma of human skin (HSC-1) cell lines ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). We observed that *PGAM1* knockdown in these cells significantly decreased their proliferative capacities ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}D), accompanied by a marked reduction in glycolytic measurements such as glucose consumption, glycolytic flux, and lactate production ([Figures 2](#fig2){ref-type="fig"}B--2D and [S3](#mmc1){ref-type="supplementary-material"}E--S3G). We observed that mRNA, protein levels, and enzymatic activities of other glycolytic enzymes were also reduced in both cell lines ([Figures 2](#fig2){ref-type="fig"}E--2G and [S3](#mmc1){ref-type="supplementary-material"}H--S3J). Notably, the decline in overall glycolytic mRNAs after *PGAM1* knockdown was restored by ectopic expression of either mouse *Pgam1* or *Pgam2* ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), probably due to the high similarity in their sequences and enzymatic activities.Figure 2Ablation of PGAM Downregulates Glycolysis *In Vitro*The impact of *PGAM1* knockdown on glycolysis in cancer cells *in vitro.* H1299 cells were transfected with *siPGAM1* (n = 3) or *scrambled* RNA (n = 3) (A--G).(A) *PGAM1*-knockdown H1299 cells were passaged according to 3T3 cell culture protocol. The proliferation curves show population doublings. The glycolytic profiles were evaluated in *PGAM1*-knockdown H1299 cells (B--G).(B--D) Glucose consumption was evaluated by measuring glucose concentration in medium (B), whereas glycolytic flux was evaluated using ^3^H-labeled glucose (C). Lactate production was determined by the measurements of lactate concentration in medium (D).(E) The mRNA levels for glycolytic enzymes were assessed. Data are relative to those in *scrambled* RNA-transfected H1299 cells. ∗p \< 0.05 and ∗∗p \< 0.005, Student\'s t test.(F) The protein levels of the indicated glycolytic enzymes were analyzed by immunoblot using anti-aldolase (ALDO), anti-GAPDH, anti-PGK1, anti-PGAM, anti-enolase1 (ENO1), and anti-actin antibodies. Intensity of immunoblotting bands was normalized to that of actin. Relative values were shown, compared with *scrambled* RNA-transfected H1299 cells.(G) Enzymatic activity of aldolase, GAPDH, PGK, PGAM, and enolase was measured by spectrometric assay.(H and I) *Pgam1* was ablated in primary MEFs from *Pgam1*^*flox/flox*^ mice harboring *Cre-ER* by treatment with 4-hydroxytamoxifen (4-OHT) for 4 days. (H) PGAM protein levels in the indicated MEFs were analyzed by immunoblotting. (I) Comparison of glycolytic mRNAs among the indicated MEFs after 4-OHT treatment (*n* = 3). *Cre(−)*; *Pgam1*^*flox/flox*^ MEFs, *Cre(+)*; *Pgam1*^*flox/flox*^ + *Cre-ER* MEFs.Data are relative to those in control. ∗p \< 0.05 and ∗∗p \< 0.005, Dunnett\'s multiple comparison test. Data represent the mean ± SEM.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Next, *Pgam1*^*flox/flox*^ MEFs expressing *Cre*-ER were generated by crossing *CAG-Cre-ER-*Tg mice and *Pgam1*^*flox/flox*^ mice, which we established ([Figure S4](#mmc1){ref-type="supplementary-material"}C). *Pgam1* mRNA and protein were efficiently ablated after 4-hydroxytamoxifen (4-OHT) treatment of these MEFs ([Figures 2](#fig2){ref-type="fig"}H and 2I), followed by a premature senescent growth arrest ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). However, glycolytic mRNA expression in these cells was similar to *Pgam1*-intact cells ([Figure 2](#fig2){ref-type="fig"}I). Similar results were obtained following transfection with *Pgam1* siRNA in primary MEFs and human fibroblast WI-38 cells, which predominantly express PGAM1 ([Figures S4](#mmc1){ref-type="supplementary-material"}F and S4G). Collectively, the abrogation of PGAM in standard cells did not affect the levels of other glycolytic mRNAs, in sharp contrast to our findings in cancer cells.

PGAM Attenuates p53 Phosphorylation and Interacts with Chk1 {#sec2.3}
-----------------------------------------------------------

In addition to the susceptibility of globally PGAM-overexpressing mice to skin carcinogenesis ([Figure 1](#fig1){ref-type="fig"}), we previously reported that PGAM was ubiquitinated via the Mdm2/p53 axis under senescence-inducing stress ([@bib28]). We also noticed that, in prematurely senescent MEFs by *Pgam1* ablation, the levels of several p53 targets (*p21*^*Cip*^, *Bax*, and *Fas*) and *p16*^*ink4*^ were significantly increased ([Figure 3](#fig3){ref-type="fig"}A). To gain insights into the molecular mechanism of glycolytic regulation by PGAM, we further investigated the possible link between PGAM and the tumor suppressor p53. As p53 activity and protein stability are regulated largely by post-transcriptional modification including its phosphorylation, we examined the p53 profile under oncogenic stress both in *Pgam2*-Tg and control MEFs expressing Ras-G12V. The protein levels of p21 and Mdm2, downstream effectors of p53, were upregulated in Ras-G12V-expressing control MEFs but were moderately impaired in Ras-G12V-expressing *Pgam2*-Tg MEFs ([Figure 3](#fig3){ref-type="fig"}B). Oncogene-induced stress also upregulated p53 protein levels in control MEFs, accompanied by the enhanced phosphorylation of serine residues 18 and 23 ([@bib7]). In contrast, in Ras-G12V-expressing *Pgam2*-Tg MEFs, p53 serine 23 phosphorylation was largely impaired compared with control, whereas serine 18 phosphorylation was moderately downregulated ([Figure 3](#fig3){ref-type="fig"}B). We also observed that ectopic expression of PGAM1 also suppresses p53 serine 23 phosphorylation in MEFs under oncogene-induced stress ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We also examined the DNA damage response in H1299 cell line with transfected WT p53. Similarly, p53 phosphorylation at serine 20, corresponding to serine 23 in mouse p53, was attenuated by ectopic PGAM expression during etoposide-induced DNA damage in H1299 cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). These data indicate that PGAM partially interferes with p53 function by impacting phosphorylation at serine 23.Figure 3PGAM Interacts with and Modulates p53 Phosphorylation by Chk1(A) The mRNA levels for *p16*^*Ink4*^ and p53 targets (*p21*^*Cip*^, *Bax*, and *Fas*) were analyzed by quantitative PCR in the indicated MEFs. Indicated MEFs were treated with or without 4-OHT for 4 days, as in [Figure 2](#fig2){ref-type="fig"}H.(B) The assessment for the effect of PGAM overexpression on the profiles of p53, Mdm2, p21, Chk1, and Chk2. Oncogenic Ras (Ras-G12V) was ectopically expressed in control (wild-type) and *Pgam2-Tg* MEFs via retroviral infection.(C) Immunoprecipitation assay was performed using *p53*^*−/−*^ MEFs expressing Chk1-myc-his with or without PGAM-FLAG. MEFs expressing PGAM1-FLAG (upper) or PGAM2-FLAG (lower) were examined. After treatment with 20 μM MG132 for 3 h, cells were lysed and immunoprecipitated with an anti-FLAG antibody and immunoblotted for Chk1 and FLAG.(D) Schematic diagram of various fragments of PGAM2: full-length (T1), N-terminal (TN), middle-region (T4), and C-terminal (TC) fragments (upper panel). The binding of each fragment to Chk1 was assessed by co-immunoprecipitation (lower panels). Extracts from *p53*^*−/−*^ MEFs transfected with the indicated plasmids were immunoprecipitated with an anti-FLAG antibody.(E) Interaction between endogenous Chk1 and PGAM protein was evaluated with immunoprecipitation in H1299 and WI-38 cells.(F) *In vitro* phosphatase activity against various peptides, phospho-p53 (Ser15), phospho-p53 (Ser20), and phospho-p53 (Ser15/Ser20) was determined using recombinant PGAM1, PGAM2, or λPPase. The peptide sequences of phospho-p53 are shown in [Figure S5](#mmc1){ref-type="supplementary-material"}F. The amount of released phosphate from phosphopeptides was monitored.∗p \< 0.05 and ∗∗p \< 0.005, Dunnett\'s multiple comparison test. Data represent the mean ± SEM.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

p53 phosphorylation at serine 23 after DNA damage and oncogenic stress is mediated either by Chk1 or Chk2, checkpoint serine/threonine kinases, followed by p53 stabilization and activation ([@bib38]). In cells ectopically expressing PGAM, total protein levels and phosphorylation status of Chk1 and Chk2 (serine 345 and threonine 68, respectively) ([@bib1]; [@bib55]) were comparable with control cells ([Figure 3](#fig3){ref-type="fig"}B). However, we observed that both PGAM1 and PGAM2 physically interacted with Chk1, but not with Chk2, in *p53*^*−/−*^ MEFs, as shown with an immunoprecipitation assay ([Figures 3](#fig3){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}C). To identify the Chk1-interacting domain in PGAM, a series of deletions in PGAM1- and PGAM2-FLAG were assessed for their ability to bind Chk1 ([Figures S5](#mmc1){ref-type="supplementary-material"}D and [3](#fig3){ref-type="fig"}D). Chk1-myc-his efficiently co-immunoprecipitated with full-length PGAM1- and 2-FLAG (T1) and the N-terminal one-third of PGAM (TN) but not with the other central (T4) or C-terminal fragments (TC). Consistently, endogenous PGAM protein co-immunoprecipitated with endogenous Chk1 protein in H1299 cancer cells but not in human standard cells WI-38 ([Figure 3](#fig3){ref-type="fig"}E).

Although PGAM has been shown to function as a phosphatase for metabolite ([@bib51]), it is unclear whether PGAM possesses activity as a protein phosphatase. We assessed the potential of PGAM to display protein phosphatase activity. Recombinant PGAM1 or PGAM2 proteins with intact PGAM activity were prepared from *Escherichia coli* ([Figure S5](#mmc1){ref-type="supplementary-material"}E). None of the recombinant PGAM proteins displayed any phosphatase activity against phospho-Ser/Thr peptides as a substrate, at any concentrations (125, 250, or 500 ng) or in any pH conditions tested (pH 6.2, 7.2, 8.2, and 9.2), whereas λPPase exhibited clear phosphatase activity ([Figures S5](#mmc1){ref-type="supplementary-material"}F--S5H). In addition, recombinant PGAM proteins exhibited no phosphatase activity *in vitro* against phosphopeptides that mimicked phospho-p53 (Ser15, Ser20, or Ser15/Ser20; [Figures 3](#fig3){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}F). Taken together, these data imply that PGAM interacts with and impairs p53 phosphorylation by Chk1, although PGAM is less likely to function as a protein phosphatase.

PGAM and Chk1 Cooperate to Regulate Glycolytic mRNAs {#sec2.4}
----------------------------------------------------

We noticed that the interaction of PGAM with Chk1 in *p53*^*−/−*^ MEFs was enhanced under TPA stress ([Figures 4](#fig4){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A), which upregulates glycolytic mRNAs during *in vivo* chemical tumorigenesis protocol ([Figure 1](#fig1){ref-type="fig"}E). To investigate the physiological significance of the interaction between PGAM and Chk1, we evaluated the impact of Chk1 on glycolytic mRNA profiles *in vitro*. We observed that *Chk1* knockdown in the *p53*-null cell line H1299 was followed by a significant reduction in glucose consumption, glycolytic flux, and lactate production ([Figures 4](#fig4){ref-type="fig"}B--4D). Significant reductions in glycolytic mRNAs and proteins were also observed in these cells ([Figures 4](#fig4){ref-type="fig"}E and 4F). Treatment with the Chk1 kinase inhibitor UCN01, but not that with the Chk2 kinase inhibitor (Chk2-inhibitor II), induced the downregulation of glycolytic flux and glycolytic mRNAs in H1299 cells ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). Interestingly, although a low concentration of UCN01 (50 nM) did not affect glycolytic mRNA levels in wild-type MEFs, the downregulation of glycolytic mRNAs was observed in *Pgam1*^*+/−*^ MEFs ([Figure 4](#fig4){ref-type="fig"}G), which displayed the same glycolytic profiles and proliferative capacity as those in wild-type MEFs under standard culture condition ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6G). These data support the notion that PGAM and Chk1 cooperatively affect glycolytic mRNA profiles.Figure 4Cooperation between PGAM and Chk1 Regulates Glycolytic mRNAs(A) The impact of TPA treatment on the interaction between PGAM1 and Chk1. p53^−/−^ MEFs with expression of Chk1-myc-his and PGAM1-FLAG were treated with or without 0.1 μg/mL TPA for 48 h, followed by treatment with MG132 for 3 h. The cell lysates were immunoprecipitated with an anti-FLAG antibody.(B--F) Impact of Chk1 inactivation on glycolytic profile *in Chk1* siRNA-transfected H1299 cells (*n* = 3). Glucose consumption, glycolytic flux, and lactate production were shown (B--D). The mRNA and protein levels of glycolytic enzymes were evaluated in indicated cells (E and F). Intensity of immunoblotting bands was normalized to that of actin. Relative values were shown, compared with *scrambled* RNA-transfected H1299 cells.(G) Comparison of glycolytic mRNAs between WT (*n* = 3) and *Pgam1*^+/−^ MEFs (*n* = 3) with or without mild treatment of UCN01, a Chk1 kinase inhibitor at a very low UCN01 concentration (50 nM) that exhibits minimal effect in WT MEFs. Data are relative to WT MEFs, respectively.∗p \< 0.05 and ∗∗p \< 0.005, Student\'s t test.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Oncogenic Ras Pathway Is Required for the PGAM-Chk1 Interaction {#sec2.5}
---------------------------------------------------------------

To evaluate the clinical relevance of PGAM-Chk1 cooperation, the impact of PGAM/Chk1 axis on prognosis of patients with cancer was evaluated. According to the database of non-small cell lung cancer (NSCLC; jacob-00182-MSK) ([@bib9]) in PrognoScan (<http://dna00.bio.kyutech.ac.jp/PrognoScan/>) ([@bib30]), we divided 104 patients with NSCLC into four groups in terms of the abundance of *PGAM1* and *Chk1* in cancers; Low-*PGAM1* + Low-*Chk1* (n = 23), Low-*PGAM1* + High-*Chk1* (n = 12), High-*PGAM1* + Low-*Chk1* (n = 29), and High-*PGAM1* + High-*Chk1* (n = 40) ([Figure S7](#mmc1){ref-type="supplementary-material"}A). We noticed that the prognostic values were most significantly declined in High-*PGAM1* + High-*Chk1* group, compared with the others ([Figure 5](#fig5){ref-type="fig"}A).Figure 5Oncogenic Ras Enhances PGAM-Chk1 Interaction(A) Association between the survival and *PGAM1/Chk1* levels was analyzed in patients with non-small cell lung cancer (NSCLC) by PrognoScan database. The survivals of 104 patients with NSCLC (Dataset Jacob-00182-MSK) were plotted with Kaplan-Meier curve. Patients with NSCLC were divided into four groups: Low-*PGAM1*+Low-*Chk1* (black; n = 23), Low-*PGAM1*+High-*Chk1* (blue; n = 12), High-*PGAM1*+Low-*Chk1* (green; n = 29), and High-*PGAM1*+High-*Chk1* (orange; n = 40). ∗p \< 0.05 and ∗∗p \< 0.005, Log rank test.(B) Summary of glycolytic mRNA downregulation by *PGAM1-*knockdown in 15 cancer cell lines tested. Original data of glycolytic mRNA expression were shown in [Figure S7](#mmc1){ref-type="supplementary-material"}B. (−), \<20% reduction; (+), reduction from 20 to 40%; (++), \>40% reduction. ∗p \< 0.05 and ∗∗p \< 0.005, Student\'s t test.(C) Summary of correlation coefficients between *Chk1* and glycolytic genes, which were evaluated in dataset of 26 NSCLC cell lines. All data were obtained from DBKERO. NSCLC cell lines were classified into two subgroups according to gene aberrations of *p53* and *Ras* pathways as shown in [Table S2](#mmc1){ref-type="supplementary-material"}.(D) The impact of Ras-G12V expression on PGAM-Chk1 binding. His-tagged protein pull-down assay was performed in indicated cells. PGAM1- or PGAM2-FLAG proteins were detected in left or right panel, respectively.(E--H) The impact of MEK and RSK inhibition against PGAM-Chk1 interaction. H1299 cells were treated with either U126 (MEK inhibitor) or BI-D1870 (RSK inhibitor). Immunoprecipitation assay was performed to evaluate the interaction between PGAM and Chk1 (E and F). Phosphorylation of Thr202/Tyr204 on ERK1/2 and Ser112 on Bad, which is downstream target of MEK/RSK pathway, was analyzed for assessment of U126 and BI-D1870, respectively. Glycolytic flux was measured in indicated cells (G and H).See also [Figures S7](#mmc1){ref-type="supplementary-material"} and [S8](#mmc1){ref-type="supplementary-material"}.

Then, we addressed the question of whether the PGAM/Chk1 axis is involved in any cancer-related genetic events. In addition to H1299 and HSC-1 ([Figures 2](#fig2){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}H), we evaluated the impact of *PGAM1* siRNA among thirteen other cancer cells, including skin, breast, colon, bone, and liver cancer cell lines. Among these 15 in total, four cancer cell lines (H1299, HSC-1, SW480, and DLD-1) displayed the most prominent changes in glycolytic mRNAs (*ALDO1, TPI, GAPDH*, and *ENO1*) following *PGAM1* knockdown ([Figures 5](#fig5){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}B). For the clinical practice of precision medicine, subsets of oncogene and tumor suppressors are tested to select tailor-made therapy for individuals; for example, 50 cancer-related genes are listed according to [@bib44] ([Table S1](#mmc1){ref-type="supplementary-material"}). We surveyed 15 cancer cell lines we tested, regarding the mutations in these 50 cancer-related genes according to previous studies ([@bib4]; [@bib13]; [@bib17]; [@bib21]; [@bib34]). We noticed that aberrations both in the p53 and Ras pathways were the most common genetic features, shared in these four cell lines (H1299, HSC-1, SW480, and DLD-1) displaying significant glycolytic decline by *PGAM1* knockdown ([Table S1](#mmc1){ref-type="supplementary-material"}). As patients with NSCLC with High-*PGAM1* + High-*Chk1* were classified in low-prognosis subgroup ([Figure 5](#fig5){ref-type="fig"}A), we also analyzed the PGAM/Chk1 axis in 26 human lung adenocarcinoma cells. Based on the database of Kashiwa Encyclopedia for human genome mutations in Regulatory regions and their Omics contexts (DBKERO; <http://kero.hgc.jp/>) ([@bib40]), these 26 cells are classified into two subgroups; cells with genetic aberrations either in the p53 or Ras pathway (n = 14) and those with aberrations in both (n = 12) ([Table S2](#mmc1){ref-type="supplementary-material"}). Then, we analyzed Pearson correlation between the levels of *Chk1* and glycolytic enzymes. Correlation coefficient between *Chk1* and most glycolytic enzymes (*HK2, GPI, ALDOA, TPI, GAPDH, PGK1, PGAM1, ENO1, and PKM1*) is high (over 0.4) in the subgroup with aberrations in both, whereas only that between *Chk1* and *TPI* is high in the former subgroup ([Figures 5](#fig5){ref-type="fig"}C, [S7](#mmc1){ref-type="supplementary-material"}C and S7D).

Consistent with these implications on the significance of Ras pathway against PGAM/Chk1 axis, we noticed that PGAM-Chk1 binding is enhanced by the expression of oncogenic Ras-G12V in *p53*^*−/−*^ MEFs ([Figure 5](#fig5){ref-type="fig"}D). To gain the molecular insight on the impact of Ras pathway against PGAM-Chk1 interaction, we applied several inhibitors for the downstream kinases of canonical Ras pathway in H1299; U126 (MEK inhibitor), BI-D1870 (inhibitor for ribosomal S6 kinase \[RSK\], a downstream kinase of MEK), and Triciribine (Akt kinase inhibitor). Although Akt inhibition unlikely affected the PGAM-Chk1 interaction ([Figure S8](#mmc1){ref-type="supplementary-material"}A), the inactivation of MEK/RSK interferes the binding between PGAM-Chk1 ([Figures 5](#fig5){ref-type="fig"}E and 5F), followed by significant reduction in glycolytic flux ([Figures 5](#fig5){ref-type="fig"}G and 5H). Thus, oncogenic Ras signals via MEK/RSK pathway are much involved in PGAM-Chk1 interaction.

Nutlin-3a Interferes with the PGAM-Chk1 Interaction {#sec2.6}
---------------------------------------------------

Next, we addressed the question of whether interference with the PGAM-Chk1 interaction affects glycolysis. Nutlin-3a is a compound originally designed to inhibit the physical binding between p53 and Mdm2 ([Figure S8](#mmc1){ref-type="supplementary-material"}B) ([@bib48]). We examined the effect of Nutlin-3a on PGAM protein, as PGAM also binds Mdm2 under senescence-inducing stress ([@bib28]). Nutlin-3a did not affect the enzymatic activity of recombinant PGAM *in vitro*, even with the increased concentrations tested ([Figure S8](#mmc1){ref-type="supplementary-material"}C). Although PGAM-Mdm2 binding was not affected by Nutlin-3a ([Figures 6](#fig6){ref-type="fig"}A and [S8](#mmc1){ref-type="supplementary-material"}D), Nutlin-3a treatment strikingly abolished PGAM-Chk1 binding in *p53*^*−/−*^ MEFs ([Figures 6](#fig6){ref-type="fig"}B and [S8](#mmc1){ref-type="supplementary-material"}E). We also treated *p53*-null H1299 cells with Nutlin-3a to disrupt PGAM-Chk1 binding to evaluate the effect on glycolytic regulation ([Figure S8](#mmc1){ref-type="supplementary-material"}F). Indeed, glycolytic flux and glycolytic mRNAs in H1299 cells were downregulated by Nutlin-3a in a dose-dependent manner ([Figures 6](#fig6){ref-type="fig"}C and 6D).Figure 6Cooperation of PGAM and Chk1 for Glycolytic Regulation Is Abolished by Interfering with Their Binding(A and B) Immunoprecipitation assay or His-tagged protein pull-down assay was performed to evaluate the effect of Nutlin-3a on the interaction between PGAM and Mdm2 (A) or PGAM-Chk1 binding (B). *p53*^*−/−*^ MEFs expressing indicated vectors were prepared. Cells were exposed to 5 or 10 μM Nutlin-3a for 48 h. After treatment with 20 μM MG132 for 3 h, cell lysates were collected. PGAM2-FLAG proteins were immunoprecipitated by anti-FLAG antibody (A) or Chk1-myc-his proteins were precipitated by Ni-NTA beads (B).(C and D) The effect of Nutlin-3a on glycolytic profile. Comparison of glycolytic flux (C) and glycolytic mRNAs (D) among H1299 cells treated with indicated concentration of Nutlin-3a for 48 h (n = 3). Data are relative to control cells. ∗p \< 0.05 and ∗∗p \< 0.005, Dunnett\'s multiple comparison test.(E) Diagram of the consensus motif of Nutlin-3-target proteins in the amino terminus of PGAM and p53. Consensus motifs, \[L/I/V/M\]-\[W/Y/F\]-x-x-\[L/I/V/W\], are indicated in blue and green. The alignments of the conserved consensus sequence in the amino terminus of PGAM1, 2, and p53 (human and mouse) are also presented. Orange bar, a site for Chk1 binding identified in [Figure 3](#fig3){ref-type="fig"}D. Purple bar, site for Mdm2 binding.(F) PGAM enzymatic activity was measured in Chk1-expressing *p53*^*−/−*^ MEFs retrovirally infected with the indicated vectors (empty vector, PGAM2-WT-FLAG, PGAM2-W68A-FLAG, and PGAM2-W78A-FLAG) (*n* = 3 each; upper panel). Protein levels for various versions of PGAM2-FLAG were shown by western blotting (lower panels). ∗∗p \< 0.005, Dunnett\'s multiple comparison test.(G) The Chk1-binding activity of PGAM2 mutants (W68A and W78A) compared with that of PGAM2-WT was analyzed with a His-tagged protein pull-down assay. Data represent the mean ± SEM.See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

Recently, the consensus sequence (\[L/I/V/M\]-\[W/Y/F\]-x-x-\[L/I/V/W\]) for Nutlin-3a responsive proteins, including p53, was determined by proteomic analysis ([@bib32]). We noticed that two repeats of this consensus motif are located and conserved in the N terminus of human and mouse PGAM, which overlap with the Chk1-interacting domains ([Figures 3](#fig3){ref-type="fig"}D and [6](#fig6){ref-type="fig"}E). PGAM mutants (*W68A* and *W78A*) with amino acid substitutions in these two repeats of the consensus sequence were generated by PCR mutagenesis ([Figure 6](#fig6){ref-type="fig"}E). Although the enzymatic activity and protein levels were maintained in both *W68A* and *W78A* mutants ([Figures 6](#fig6){ref-type="fig"}F and [S8](#mmc1){ref-type="supplementary-material"}G), PGAM-Chk1 binding was largely impaired ([Figures 6](#fig6){ref-type="fig"}G and [S8](#mmc1){ref-type="supplementary-material"}H). Thus, Nutlin-3a interferes with the PGAM-Chk1 interaction and the maintenance of glycolytic features but not with the enzymatic activity of PGAM.

Physical Interaction between PGAM and Chk1 Is Essential for Both Maintenance of Glycolysis and Proliferative Potential in Cancerous Cells {#sec2.7}
-----------------------------------------------------------------------------------------------------------------------------------------

As PGAM mutants for Nutlin consensus motif (*W68A* and *W78A*) attenuate the interaction with Chk1 in *p53*^*−/−*^ MEFs with or without Ras-G12V expression ([Figures S8](#mmc1){ref-type="supplementary-material"}I and S8J), we evaluated the physiological impact of these mutants (*W68A* and *W78A*) in the conditions with or without Ras-G12V. For this purpose, Chk1-expressing *p53*^*−/−*^ MEFs with or without Ras-G12V were prepared, followed by retroviral infection with various versions of PGAM. In the absence of Ras-G12V, co-expression of Chk1 with WT-, W68A-, or W78A-PGAM resulted in similar profiles for overall glycolytic mRNAs and proliferative capacity ([Figures S8](#mmc1){ref-type="supplementary-material"}K, [S9](#mmc1){ref-type="supplementary-material"}D, [7](#fig7){ref-type="fig"}F, S8L, S9F, and S9G). In sharp contrast, in the presence of Ras-G12V, ectopic expression of PGAM-WT in Chk1-expressing *p53*^*−/−*^ MEFs increased the glycolytic parameters (glucose consumption, glycolytic flux, and lactate production), compared with the vector control ([Figures 7](#fig7){ref-type="fig"}A--7C and [S9](#mmc1){ref-type="supplementary-material"}A--S9C). Consistently, the expression of glycolytic mRNAs and proteins were upregulated in these cells ([Figures 7](#fig7){ref-type="fig"}D, 7E, [S9](#mmc1){ref-type="supplementary-material"}D, and S9E). In the same genetic background, however, PGAM-W68A and W78A mutants displayed no such enhancement in glycolytic profiles ([Figures 7](#fig7){ref-type="fig"}A--7E and [S9](#mmc1){ref-type="supplementary-material"}A--S9E).Figure 7W68A and W78A in PGAM, Binding-Deficient Mutations with Intact Enzyme Activity, Abolished the Enhancement of Glycolytic Profiles and Proliferative Capacity in the Presence of Ras-G12V.(A--E) Comparison of glycolytic profiles among the cells expressing PGAM2 variants (WT, W68A, or W78A) in the presence of Ras-G12V. Glucose consumption (A), glucose flux (B), and lactate production (C) were analyzed among indicated cells on the common genetic background of *p53*^*−/−*^ with Ras-G12V and Chk1 (*n* = 3). The mRNA and protein levels of glycolytic enzymes were also evaluated in indicated cells (D and E). Intensity of immunoblotting bands was normalized to that of actin. Data are relative to controls expressing the empty vector.(F) The effect of indicated PGAM2 variants on cell growth was assessed by crystal-violet staining in Chk1-expressing *p53*^*−/−*^ MEFs with or without Ras-G12V.(G and H) *In vivo* tumor growth assay in nude mice. *p53*^*−/−*^ MEFs, expressing Ras-G12V, Chk1, and the indicated versions of PGAM2, were injected subcutaneously into nude mice (n = 6). (G) Representative images of tumors. (H) Measurement of tumor volumes are shown. ∗p \< 0.05 and ∗∗p \< 0.005, Dunnett\'s multiple comparison test. Data represent the mean ± SEM.(I) Schematic model on the significance of PGAM-Chk1 interaction in cancerous glycolysis. Oncogenic Ras augmented PGAM-Chk1 interaction, followed by enhanced glycolysis in cancer. Genetic or chemical ablation of the interaction abrogated such enhancement.See also [Figures S8--S11](#mmc1){ref-type="supplementary-material"}.

Strikingly, in the presence of Ras-G12V, both the *in vitro* proliferative capacity and *in vivo* tumor growth of PGAM-WT overexpressing cells were much enhanced than control ([Figures 7](#fig7){ref-type="fig"}F--7H, [S8](#mmc1){ref-type="supplementary-material"}L, and [S9](#mmc1){ref-type="supplementary-material"}F--S9I). In the same genetic background, however, the cells with binding-deficient mutations (*W68A* and *W78A*) showed the similar proliferative potentials *in vitro* and *in vivo* to those in control ([Figures 7](#fig7){ref-type="fig"}F--7H, [S8](#mmc1){ref-type="supplementary-material"}L, and [S9](#mmc1){ref-type="supplementary-material"}F--S9I). Next, we addressed the question whether *W68A* or *W78A* mutation abolished PGAM-Chk1 binding through modulating PGAM dimerization. For this purpose, NanoLuc Binary Technology (NanoBiT) system (Promega) is applied, which enables us to quantify protein-protein interaction between the proteins with large and small NanoBiT tag ([Figure S10](#mmc1){ref-type="supplementary-material"}A) ([@bib10]). We purified recombinant PGAM1, 2-WT, W68A, and W78A proteins with NanoBiT tags from the extract of bacteria ([Figure S10](#mmc1){ref-type="supplementary-material"}B). We observed these recombinant PGAM proteins displayed similar intact enzymatic activity ([Figure S10](#mmc1){ref-type="supplementary-material"}C). Consistently, the dimerization of either PGAM versions displayed the similar values of Kd (dissociation constant), shown by the saturation curves of NanoBiT detection; 62.5 to 67.1 nM for various versions of PGAM1 and 60.6 to 65.9 nM for those of PGAM2 ([Figure S10](#mmc1){ref-type="supplementary-material"}D). Thus, PGAM-W68 and W78A did not affect dimerization and enzymatic activity of PGAM. However, we noticed that monomer forms of PGAM were much abundant in H1299 cancer cells, compared with those in standard WI-38 cells ([Figure S10](#mmc1){ref-type="supplementary-material"}E). These findings support the possibility that nonenzymatic PGAM is more accumulated in cancer cells.

Finally, we evaluated the impact of enzymatic PGAM mutants in the same setting. As the patients with PGAM deficiency were previously reported ([@bib31]), the point mutation *R90W* in the patients abolished PGAM enzymatic activity ([@bib45]). We generated cDNA clone of PGAM1 and 2 with *R90W* mutation. We observed that such mutation in both PGAM isoforms abolished PGAM activity ([Figures S11](#mmc1){ref-type="supplementary-material"}A and S11B) but still retains proliferative advantage compared with vector control, in Chk1 and Ras-G12V-expressing p53^−/−^ MEFs ([Figures S11](#mmc1){ref-type="supplementary-material"}C and S11D).

Thus, in accordance with the observation of chemically interfering by Nutlin, the genetical interference of PGAM-Chk1 binding with intact PGAM activity (*W68A*, *W78A* mutations) abolished cancerous proliferation and enhanced glycolytic profiles, in the presence of oncogenic Ras ([Figure 7](#fig7){ref-type="fig"}I).

Discussion {#sec3}
==========

Here we demonstrated a previously unappreciated regulatory mechanism for cancerous glycolysis via the PGAM-Chk1 interaction. Genetic and chemical dissection for its interaction disclosed a "non-enzymatic" role for PGAM, especially under oncogenic Ras expressing conditions. Thus, we unveiled the noteworthy impact of interfering with the PGAM/Chk1 axis in the cancerous glycolysis.

First, our data indicate the evident genetic link between PGAM and the global enhancement of glycolytic profiles frequently observed in cancerous cells. We found a molecular interaction between PGAM and Chk1 as notable glycolytic regulator, which is operating in cancer cells, not in standard cells. Moreover, in addition to the data on the prognosis of patients with cancer, several close correlations between Chk1/PGAM and glycolytic enzymes identified oncogenic Ras mutations, which are highly prevalent both in human cancers and DMBA-treated tissues ([@bib20]), as enhancer of PGAM-Chk1 interaction. Although the other research has also emphasized the distinct impact of PGAM in cancer metabolism ([@bib12]; [@bib47]), we identified the essential effect of PGAM on the boost of glycolysis in the cancerous conditions.

Second, our study also disclosed the key metabolic role of Chk1 for glycolytic regulation in cancer. Chk1, initially identified as a checkpoint kinase, was known to induce cell-cycle arrest after its activation during DNA damage or senescence-inducing stress ([@bib37]). Other studies, however, have suggested the opposing notions that Chk1 would be the critical driver of cellular proliferation in ES cells and cancer cells *in vitro* ([@bib26]; [@bib39]) and in carcinogenic events *in vivo* ([@bib43]). Interestingly, Chk1 was reported to be regulated by RSK, the downstream kinase of Ras pathway, during cell cycle progression ([@bib25]). RSK is upregulated in many types of cancer including lung cancer and promotes cancerous proliferation ([@bib18]), whose impacts on the Warburg effect were scarcely reported. As our findings suggest that oncogenic Ras/RSK activation are closely involved in PGAM-Chk1 binding, the opposing roles of Chk1 with respect to cell proliferation would be cellular-context dependent, including the modulation of Ras/RSK pathway.

Third, our findings in the binding-deficient mutants of PGAM implicate that regardless of its enzymatic activity, PGAM plays a critical role in the regulation of glycolytic upregulation. Although neither the phosphatase nor enzymatic activity of PGAM was found to be required for the functional cooperation with Chk1, the physical interaction between PGAM and Chk1 is essential for glycolytic upregulation. These findings are rather consistent with the previous notion that the multifaceted roles of some enzymes are independent of their catalytic activity (Mdm2 for [@bib35]; PP2A for [@bib41]). It is possible that in cancerous cells with accumulation of PGAM proteins, "nonenzymatic" PGAM cooperates with the Chk1 pathway to boost glycolysis, whose activation is required for the survival of cancers bearing oncogenic Ras mutation ([@bib8]). A plausible explanation for the Warburg effect has been proposed as follows: besides hypoxic adaptation, it might not only enable cancer cells to meet demands both for energy and biosynthesis ([@bib27]) but also protect them from oxidative damages ([@bib23]). Interestingly, the recent studies suggested that PGAM interacts with actin proteins as nonenzymatic role, to facilitate cancer motility ([@bib19]; [@bib53]). In addition to the above, the identification of nonenzymatic role for PGAM suggested that enhanced glycolysis might support proliferative capacity of rapidly dividing cells through the cooperation with Chk1.

Finally, our analysis also supported the clinical significance of PGAM-Chk1 interaction. Nutlin-3a, an anticancer drug as inhibitor of p53-Mdm2 binding ([@bib3]), interfered with the PGAM-Chk1 interaction in a p53-independent manner but not with PGAM enzymatic activity. Thus, Nutlin-3a likely also functions as a glycolytic modulator through interfering with the PGAM-Chk1 interaction. Since the discovery of the Warburg effect, cancer metabolism has long been assumed to be a potential anticancer therapeutic target. However, enzymatic inhibition of glycolysis has failed in clinical trials as anticancer drugs owing to their profound adverse effects ([@bib15]). Therefore, targeting the binding between PGAM and Chk1 would represent a potential candidate strategy for anti-cancer therapy.

Limitation of the Study {#sec3.1}
-----------------------

Skin carcinogenesis protocol was performed in *Pgam2-Tg* mice, whereas *in vivo* tumor formation assay in nude mice was performed in PGAM1- or PGAM2-expressing cells. In the future, it would be worthy to explore the PGAM/Chk1 axis in human clinical samples.
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